Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer

被引:10
|
作者
Stanciu, Adina Elena [1 ]
Hurduc, Anca Elena [2 ]
Stanciu, Marcel Marian [3 ]
机构
[1] Inst Oncol Bucharest, Dept Carcinogenesis & Mol Biol, 252 Fundeni, Bucharest 022328, Romania
[2] Inst Oncol Bucharest, Dept Nucl Med, Bucharest, Romania
[3] Univ Politeh Bucharest, Dept Elect Engn Fac, Bucharest, Romania
关键词
Amino acids; blood pressure; cardiac pumping; oncology; peptides and proteins; thyroid diagnostics and treatment; thyroid hormones; REMNANT ABLATION; HEART-FAILURE; DISEASE; BIOMARKERS; RISK; RECOMMENDATIONS; HYPOTHYROIDISM; RADIOIODINE; CARCINOMA; EVENTS;
D O I
10.1080/00365513.2016.1230883
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: We aimed to investigate the effects of thyroid hormone withdrawal on N-terminal prohormone forms of atrial natriuretic peptide (NT-proANP) and brain natriuretic peptide (NT-proBNP) during radioiodine therapy in female patients with differentiated thyroid cancer (DTC).Methods: Serum concentrations of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), NT-proANP and NT-proBNP were measured in 51 female patients with DTC (48.74.2 years) at three time-points: day of radioiodine therapy (t1 - under acute hypothyroidism), 5 days after radioiodine (t2 - under acute hypothyroidism) and 3 months after radioiodine (t3 - under TSH suppression). Thirty healthy euthyroid women served as controls (42.85.6 years).Results: At t1/t2/t3, median NT-proANP was 5.2/1.7/487pmol/L vs. 297.7pmol/L in control group (p<0.001), median NT-proBNP was 50.1/36.5/79.5pmol/L vs. 64.5pmol/L (p<0.001) and median NT-proANP/NT-proBNP ratios was 0.20/0.18/4.81 vs. 4.14 (p<0.001). In acute hypothyroidism, FT3 levels were positively correlated with NT-proANP (r=0.38, p=0.005), NT-proANP/NT-proBNP ratios (r=0.47, p=0.001), heart rate (r=0.39, p=0.005), and negatively with mean arterial blood pressure (r=-0.58, p<0.001).Conclusions: Our results indicate that NT-proANP reflects more accurately direct thyroid hormone effects than NT-proBNP. Thyroid hormone-dependent hemodynamic effects seem to be overlapped on the direct stimulatory effect of thyroid hormones on NT-proANP secretion by cardiac myocytes.
引用
收藏
页码:626 / 631
页数:6
相关论文
共 50 条
  • [41] Causes of False-Positive Radioactive Iodine Uptake in Patients with Differentiated Thyroid Cancer
    Wu, Karin
    Ozomaro, Uzoezi
    Flavell, Robert
    Pampaloni, Miguel
    Liu, Chienying
    CURRENT RADIOLOGY REPORTS, 2021, 9 (06)
  • [42] Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer
    Bandeira, Leonardo
    Padovani, Rosalia do Prado
    Ticly, Ana Luiza
    Cury, Adriano Namo
    Scalissi, Nilza Maria
    Silveira Marone, Marilia Martins
    Ferraz, Carolina
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (06): : 590 - 599
  • [43] Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
    Gigliotti, Benjamin J.
    Jasim, Sina
    ENDOCRINE, 2024, 83 (02) : 251 - 258
  • [44] Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer
    Hu, Tianpeng
    Meng, Zhaowei
    Zhang, Guizhi
    Jia, Qiang
    Tan, Jian
    Zheng, Wei
    Wang, Renfei
    Li, Xue
    Liu, Na
    Zhou, Pingping
    Upadhyaya, Arun
    MEDICINE, 2016, 95 (35)
  • [45] Long-term effect of postoperative radioactive iodine therapy on parathyroid function in patients with differentiated thyroid cancer
    Merdin, Fatma Avci
    Canpolat, Asena Goekcay
    Corapcioglu, Demet
    Soydal, Cigdem
    Sahin, Mustafa
    ANNALS OF NUCLEAR MEDICINE, 2025, 39 (03) : 278 - 284
  • [46] Definition and management of radioactive iodine-refractory differentiated thyroid cancer
    Schlumberger, Martin
    Brose, Marcia
    Elisei, Rosella
    Leboulleux, Sophie
    Luster, Markus
    Pitoia, Fabian
    Pacini, Furio
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05) : 356 - 358
  • [47] Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
    Worden, Francis
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (06) : 267 - 279
  • [48] Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer
    Volpe, Fabio
    Nappi, Carmela
    Zampella, Emilia
    Di Donna, Erica
    Maurea, Simone
    Cuocolo, Alberto
    Klain, Michele
    CURRENT ONCOLOGY, 2024, 31 (07) : 3870 - 3884
  • [49] Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer
    Guo, Yiling
    Zhang, Yingnan
    Chen, Zuowei
    Xin, Zhenfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (05) : 1847 - 1850
  • [50] Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis
    Fu, H.
    Ma, C.
    Tang, L.
    Wu, F.
    Liu, B.
    Wang, H.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (01) : 121 - 128